Sintenal

Quick links to important sections

Sintenal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sintenal

Property Description
Active ingredient Simvastatin (INN)
Form Tablet (most common)
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
General purpose Lipid-modifying agent (lowers harmful cholesterol)
Origin Semi-synthetic Derivative

What Type of Medicine is Sintenal?

Sintenal is a prescription-only medication whose active ingredient is Simvastatin, classifying it as a statin, a recognized type of antilipemic agent used to manage blood lipid levels. The drug's active component, Simvastatin, is an HMG-CoA Reductase Inhibitor, reflecting its specific action on a key enzyme in the body's cholesterol production pathway. Simvastatin is a semi-synthetic derivative—originally based on a natural compound but manufactured through controlled chemical synthesis for consistency and purity. Sintenal is provided as a single-component product in the form of a tablet intended for oral administration, meaning its therapeutic effects are systemic.


Simvastatin: Composition and General Purpose

The primary general purpose of Sintenal is to serve as a foundational lipid-modifying therapy aimed at reducing the concentration of harmful cholesterol in the bloodstream. By blocking the HMG-CoA reductase enzyme, Simvastatin effectively curtails the liver's internal synthesis of cholesterol. This targeted reduction prompts the liver to increase its capacity to clear cholesterol from the bloodstream, specifically the Low-Density Lipoprotein Cholesterol (LDL-C). This specific mechanism is crucial for achieving the general therapeutic goal of significantly lowering the concentration of harmful cholesterol and supporting a healthier balance of blood lipids.

Regulatory References

  1. Simvastatin Drug Label (Pharmacological Classification)
  2. Simvastatin - LiverTox (Mechanism of Action)

What side effects are possible with Sintenal?

The possible side effects and safety information for Sintenal (Simvastatin) are formally classified by government regulatory authorities based on clinical data and post-marketing experience. Adverse reactions are grouped by frequency and by the affected System-Organ-Class (SOC).

Official Frequency Classifications

Frequency Examples of Adverse Reactions (SOC)
Common (1/100 to 1/10) Headache, gastrointestinal effects (e.g., constipation, abdominal pain), and myalgia (muscle pain).
Uncommon (1/1,000 to 1/100) Myopathy, dyspepsia, rash, pruritus, and dizziness.
Rare (1/10,000 to 1/1,000) Pancreatitis, hepatitis, jaundice, peripheral neuropathy, and rhabdomyolysis.
Very Rare (< 1/10,000) Fatal and non-fatal hepatic failure, insomnia, and gynecomastia.
Not Known (Cannot be estimated) Interstitial lung disease, tendinopathy, and immune-mediated necrotising myopathy (IMNM).

Serious Adverse Reactions and Safety Constraints

The label explicitly documents rare but serious adverse reactions, notably Rhabdomyolysis—a severe muscle breakdown that can be complicated by acute renal failure—and instances of Fatal and non-fatal hepatic failure. The drug is formally contraindicated in patients with active liver disease or unexplained persistent elevations of liver enzymes. Use during pregnancy and lactation is also contraindicated.

Time-related safety patterns are noted: the risk of myopathy is highest during the first year of treatment with the highest approved dose, and cognitive impairment reports are generally considered reversible upon discontinuation. Regulatory documentation also restricts co-administration with certain strong enzyme inhibitors (e.g., strong CYP3 A4 inhibitors) due to increased risk of muscle toxicity.

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented information from governmental regulatory sources regarding Simvastatin (Sintenal) overdosage.


Overdose Scope and Required Actions

Feature Official Regulatory Statement
Documented Manifestations Acute overdose is generally not associated with specific symptoms; reported cases, even at doses up to 3.6 g, resulted in recovery without sequelae (lasting effects).
Severe Risks The primary severe risk of overexposure is Rhabdomyolysis (severe muscle breakdown) and subsequent acute renal failure, which are dose-related toxicities requiring urgent care.
Emergency Actions Required Immediate medical attention must be sought, and a Poison Control Center should be contacted immediately upon suspected overdose.

Overdose Management Profile

Official guidance states that no specific antidote is known for Simvastatin overdosage. Management must therefore be symptomatic and consist of adopting general supportive measures. The dialyzability of the drug and its metabolites is not known.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by the absence of acute specific symptoms and the resulting mandate to treat it with general supportive measures. This lack of a known acute symptomatic profile and the absence of a specific antidote nevertheless trigger the requirement for immediate medical help due to the documented potential for severe dose-related systemic toxicity, namely the life-threatening risk of rhabdomyolysis and subsequent kidney damage.

Therapeutic Uses of Sintenal

Sintenal (Simvastatin) is a prescription medicine focused on managing long-term health risk rather than the relief of acute physical symptoms. It is used to address underlying, asymptomatic issues related to blood fat levels that drive major cardiovascular disease. This medication is relevant for use in conditions where supportive management of cardiovascular risk is appropriate.


Sintenal is commonly used in conditions marked by a persistent elevation of harmful lipids, including high Low-Density Lipoprotein Cholesterol (LDL-C), high triglycerides, and mixed dyslipidemia. It is also applied in high-risk scenarios such as managing established coronary heart disease and controlling risk for patients with diabetes mellitus. The therapy is relevant for supporting healthier lipid profiles, which contributes to easing the overall systemic burden related to cardiovascular risk. This usage supports groups in the management of chronic, heightened risk associated with conditions like Familial Hypercholesterolemia (HeFH) and after a stroke.

“The therapy is relevant for long-term support in contexts marked by increased discomfort or tension related to lipid disorders.”

Quick Fact: Support for Asymptomatic Dyslipidemia

The medication is applied to address symptoms related to systemic imbalance (high LDL-C and triglycerides), which may assist with maintaining cardiovascular stability and reducing the risk of events such as a heart attack or stroke.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Sintenal?

Eligibility for Sintenal (Simvastatin) is strictly defined by official regulatory labeling, outlining populations that are permitted, restricted, or absolutely prohibited from using the medicine.

Contraindications (Must Not Use):

  • Active Liver Disease: Use is prohibited for patients with active liver disease or unexplained, persistent elevation of liver enzymes.
  • Pregnancy and Lactation: Use is contraindicated for women who are pregnant or are breastfeeding.
  • Hypersensitivity: Patients with a known allergy to Simvastatin or any component of the tablet must not use it.
  • Concomitant Use: Use is strictly prohibited with potent CYP3A4 inhibitors (e.g., specific antifungals, certain antibiotics, HIV protease inhibitors) due to the increased risk of myopathy.

Age and Condition Restrictions:

  • Children: Safety and efficacy are not established for children under 10 years old.
  • Adolescents (10–17 years) are eligible only for specific conditions, such as Heterozygous Familial Hypercholesterolemia.
  • High-Dose Restriction (80 mg): Initiation of the 80 mg dose is not recommended for new patients. It is restricted only to those who have taken it for 12 months or more without muscle injury.
  • Organ Impairment: Patients with severe renal impairment require caution and may be limited to lower starting doses, as specified in the labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sintenal (Simvastatin) is subject to specific interaction-related restrictions and requirements formally documented in government regulatory labeling. The product’s interaction profile is largely structured around substances that affect its systemic exposure or impose an additive pharmacodynamic risk.

Contraindicated Combinations

Co-administration with several medicinal products is strictly contraindicated due to significantly increased plasma concentrations of Simvastatin. This prohibited list includes strong CYP3A4 inhibitors (such as certain Azole antifungals and Macrolide antibiotics), as well as Cyclosporine, Danazol, and Gemfibrozil.

Exposure-Modifying Agents

Agents that inhibit the CYP3A4 enzyme or the OATP1B1 transporter are documented to increase Simvastatin exposure. Regulatory labels impose mandatory maximum daily dose restrictions for co-administration with these medicines. For example, the maximum Simvastatin dose is limited to 10 mg/day when taken with Verapamil or Diltiazem, and 20 mg/day with Amlodipine or Amiodarone.

Other Documented Interactions

Simvastatin carries a documented additive risk of muscle-related toxicity when co-administered with medicines like Colchicine or other fibrates. Additionally, it is officially documented to potentiate the effects of Coumarin Anticoagulants, leading to an increase in the International Normalized Ratio (INR).

Consumption of large quantities of grapefruit juice is restricted due to its documented effect of increasing Simvastatin plasma levels. A requirement for timing separation is also documented for co-administration with a Bile Acid Sequestrant to avoid absorption interference.

Mechanism of Action

Enzyme Inhibition and Cholesterol Synthesis Blockade

Sintenal's active form works by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase ( HMG-CoA reductase), the rate-limiting enzyme in the liver's cholesterol-producing pathway (mevalonate pathway). This molecular blockade directly curtails the internal synthesis of new cholesterol within liver cells.

Systemic Cholesterol Clearance Activation

The reduction of internal cholesterol forces the liver to compensate by significantly increasing the number of Low-Density Lipoprotein Receptors ( LDL-R) on its surface. This compensatory mechanism enhances the liver's capacity to actively capture and clear LDL-C from the bloodstream, resulting in a reduction in circulating plasma LDL-C levels.

Modulation of Vascular Cell Signaling

Beyond its lipid-modulating mechanism, the enzyme inhibition also curtails the production of crucial non-sterol intermediates required for the proper function of small regulatory proteins in non-hepatic cells. This secondary mechanism modulates vascular cell signaling pathways, affecting processes related to endothelial function and inflammatory responses.

Dosage and Administration Information

How to Use Sintenal (Simvastatin)

Sintenal is administered orally as a tablet. The dosing regimen involves a once-daily intake, which should occur in the evening to align with the body’s natural lipid processes. The dose can be taken with or without food.

Standard adult therapy begins typically at 10 mg or 20 mg daily, with the maximum general recommended dose established at 40 mg once daily. Dosage adjustments are gradual, occurring only at intervals of not less than four weeks. Crucially, the 80 mg dose is strictly limited to patients who have taken it chronically (greater than or equal to 12 months) without showing signs of toxicity; it must not be used to start new treatment.

Administration Constraints and Special Use

Several instructions define the proper use context. Consumption of grapefruit juice must be avoided during therapy. If the drug is co-administered with a bile acid sequestrant, the Sintenal dose must be separated by time, taken at least 2 hours before or at least 4 hours after the sequestrant.

For specific populations, a reduced starting dose is required; for example, patients with severe renal impairment (creatinine clearance < 30 mL/min) should initiate therapy at 5 mg once daily. If a dose is missed, the patient should take it as soon as they remember, but must not double the next scheduled dose. Sintenal is intended for long-term management protocols.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sintenal

Evidence for Use in Managing High Cholesterol and Blood Lipids

Simvastatin, the active ingredient in Sintenal, was studied in clinical research contexts for conditions associated with high levels of blood fats, including high low-density lipoprotein cholesterol (LDL-C). Researchers conducted numerous large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that explored Simvastatin's use. These studies focused primarily on measuring shifts in lipid biomarker levels and monitoring the occurrence of major cardiovascular events over long periods. Studies documented that participants receiving Simvastatin showed measured changes in these key blood markers. Also, while the impact on blood biomarkers is documented in numerous studies, comparative evidence is limited regarding long-term outcomes of Simvastatin compared to all newer medications in the same class across all patient types.

Evidence for Use in Preventing Cardiovascular Events

Research examined Simvastatin's use in two high-risk scenarios: secondary prevention for patients who already have established Coronary Heart Disease (CHD), and primary prevention for asymptomatic, high-risk individuals, such as those with Diabetes Mellitus. For both groups, large-scale studies collected data on the rates of recurrent or first-time cardiovascular events (like heart attack or stroke) over follow-up periods often lasting several years. These studies were structured to observe long-term clinical endpoints. The research provides context about the study of Simvastatin in exploring long-term cardiovascular risk for these patient groups.

Long-Term Research and Areas of Uncertainty

Long-term research provides context on the durability of the study findings over many years. However, the long-term effects are not fully established for the entire lifespan of patients who begin treatment early.

Research has also been conducted in specialized patient groups, notably pediatric populations with Familial Hypercholesterolemia (HeFH). Due to the rarity of the condition, the sample sizes were modest compared to general population studies. Data for certain groups remain insufficient regarding long-term cardiovascular events into later adulthood. Furthermore, results reflect the specific conditions and populations under which they were conducted, and may not be fully applicable to every patient scenario.

Key Studies & References

  1. MRC/BHF Heart Protection Study (HPS) of cholesterol lowering with simvastatin in 20,536 high-risk individuals

Frequently Asked Questions (FAQ)

Common questions about Sintenal (FAQ)

Q: Does Sintenal have a generic or off-brand name that is cheaper?

A: The active ingredient in Sintenal is Simvastatin, which is its generic name. Official product information indicates that Simvastatin is available as a generic drug, which may be an alternative to the brand-name product.


Q: Is it normal to feel a mild stomach upset or fatigue in the first few days of taking Sintenal?

A: Regulatory documents list gastrointestinal effects, such as abdominal pain, constipation, and nausea, as common side effects. Headache is also commonly reported. Concerns about new or persistent symptoms should be discussed with a healthcare provider.


Q: What is the expected timeline for Sintenal to start having a noticeable effect?

A: Sintenal is designed for long-term management of high cholesterol. While the body begins to process the medication immediately, the therapeutic effect, which is the lowering of cholesterol, is not instantaneous. Cholesterol levels are typically re-evaluated by a doctor as early as 2 to 4 weeks after starting treatment to check on effectiveness.


Q: Are there any specific vitamins, supplements, or herbal remedies that should not be taken with Sintenal?

A: Official labeling notes that using the herbal supplement St John's wort may reduce the effectiveness of Simvastatin. Additionally, caution is advised when taking certain lipid-modifying doses of Niacin due to the potential for an increased risk of muscle problems.


Q: Is Sintenal considered safe for older adults or elderly populations?

A: Clinical studies have generally not shown significant differences in safety between older and younger patients. However, regulatory documents note that being 65 years of age or older is listed as a potential risk factor for developing muscle-related side effects.


Q: Will Sintenal affect my ability to drive or operate machinery?

A: Dizziness and headache are listed among the documented side effects of Sintenal. Due to this possibility, individuals may need to consider their reaction to the medication before driving or operating heavy machinery.


Q: Can Sintenal be used by people who have mild to moderate kidney issues?

A: According to the official prescribing information, no dose adjustment is necessary for individuals with mild to moderate renal impairment. However, patients with severe renal impairment require a specific, lower starting dose.


Q: Do lifestyle changes, like diet and exercise, affect how well Sintenal works?

A: Yes. Official information indicates that Sintenal is to be used as an adjunct to diet, exercise, and weight loss. This means the medication is intended to complement, not replace, these other positive lifestyle measures.


Q: How long after taking Sintenal should I wait before eating or drinking certain things?

A: Sintenal can be taken with or without food. If another drug called a bile acid sequestrant is co-administered, a specific time separation is required: Sintenal must be taken at least two hours before or four hours after the sequestrant.


Q: Does Sintenal cause changes in mood or sleep patterns?

A: Official documentation lists insomnia (difficulty sleeping) as a very rare side effect. Furthermore, cognitive issues such as memory loss, forgetfulness, and confusion have been reported but are generally reversible once the medication is stopped.


Q: What are the signs of a rare but serious adverse reaction to Sintenal that require immediate attention?

A: Serious adverse reactions include severe muscle breakdown (rhabdomyolysis) and hepatic failure (liver failure). Documented signs of these serious issues include unexplained muscle pain, tenderness, or weakness and the yellowing of the skin or eyes (jaundice).


Q: Does Sintenal cause weight gain or weight loss in people who take it long-term?

A: Official adverse reaction data lists weight gain as an uncommon side effect of Simvastatin. Weight loss is not formally documented in the standard adverse reaction tables.


Q: Are there any common food interactions with Sintenal that I should be aware of?

A: The primary food interaction noted in official labeling is that consumption of large quantities of grapefruit juice is restricted as it significantly increases the level of Simvastatin in the blood, which raises the risk of side effects.


Q: What is the difference between Sintenal and the version of the drug mentioned in research studies?

A: Sintenal is the brand name used for the medication. The research studies and regulatory documents typically refer to the active ingredient by its generic name, Simvastatin.


Q: Is Sintenal safe for use in adolescents or young adults?

A: Safety and effectiveness have not been established for children under 10 years old. Adolescents (ages 10 to 17) may be eligible only for specific, severe cholesterol conditions, and females must be at least one year post-menarche.


Q: Are there different formulations of Sintenal (e.g., tablet, capsule, liquid)?

A: Sintenal is most commonly supplied and administered as an oral film-coated tablet. Depending on the specific brand, the drug is also available as an oral suspension (liquid) formulation.


Q: How long does a single dose of Sintenal stay active in the body?

A: Regulatory pharmacokinetic data shows that the active form of the drug reaches its peak concentration in the blood within 1.3 to 2.4 hours after the dose. The total amount of drug activity in the blood declines rapidly.


Q: What does 'contraindicated' mean in the context of Sintenal use?

A: The term contraindicated means that the medication must not be used in a particular situation or by a specific patient population. This restriction is enforced because the potential risk of serious harm outweighs any possible benefit of using the drug.


Q: Do any environmental factors or climates affect the storage or effectiveness of Sintenal?

A: Official instructions require that Sintenal tablets must be stored at controlled room temperature (between 20 C and 25 C). It is crucial to keep the tablets in their original container, tightly closed, to protect them from moisture.


Q: Are there clinical trials still underway for new uses or improvements to Sintenal?

A: Government databases, such as ClinicalTrials.gov, document both ongoing and completed studies involving Simvastatin. These trials explore its use in new contexts and compare it to other treatments.


Q: Why do some people report feeling no effect from Sintenal immediately?

A: Sintenal works by changing internal biochemical processes to gradually reduce cholesterol levels. Since this is a change in blood chemistry, it does not produce an immediate, noticeable physical feeling like a pain reliever would.


Q: What kind of pre-screening tests are typically done before starting a Sintenal prescription?

A: Before starting treatment, blood tests to check liver function are typically required. This is a safety precaution because the medication is strictly prohibited (contraindicated) for patients with active liver disease.


Q: Are there any dietary restrictions specifically mentioned in the Sintenal patient information leaflet?

A: The patient information leaflet explicitly mentions the restriction on consuming grapefruit juice. Other general dietary requirements are related to complementing the drug with a healthy, cholesterol-lowering diet.


Q: Does Sintenal interfere with the results of any routine medical lab tests?

A: Clinical studies have reported that Sintenal can cause elevations in certain blood markers, including liver function tests and levels of creatine kinase (an enzyme associated with muscle activity).


Q: Is there a specific mechanism by which Sintenal is metabolized or broken down by the liver?

A: Yes, regulatory information documents that Simvastatin is broken down (metabolized) in the liver primarily through a pathway involving the enzyme system known as CYP3A4.


Q: Can Sintenal be used in combination with other treatments for the same condition?

A: Sintenal is formally documented for co-administration with some other treatments. However, it is strictly contraindicated (prohibited) to combine it with certain other cholesterol-lowering drugs, such as Gemfibrozil, due to a high risk of muscle damage.


Q: What is the maximum duration of time a person should realistically take Sintenal?

A: Sintenal is intended for long-term management protocols for high cholesterol and cardiovascular risk. Clinical studies have monitored patients for follow-up periods of several years.

How should Sintenal be stored and disposed of?

Storage and Disposal of Sintenal (Simvastatin)

Sintenal tablets must be stored according to official regulatory labeling to ensure stability and safety.

Storage Requirements

Item Official Labeled Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F), with permitted excursions up to 30 C.
Protection Store in the original container, tightly closed, to protect from moisture.
Child Safety Keep out of the reach of children.

Disposal

Unused or expired Sintenal should be disposed of according to local regulations or a pharmacy take-back program. It is generally advised not to discard the medication via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sintenal found in:

A-Z Index: